Create a free account to see ACCE Scores
Sign up for free to unlock scores, score breakdowns, and stock analysis.
ESPR
↓ PDF (Pro)Esperion Therapeutics Inc. Common Stock
HealthcareDrug Manufacturers - Specialty & GenericUnited StatesNASDAQ
$3.13
+0.55%today
MKT CAP
$806M
+49.8% · 1Y
Earnings History
-40.0%
+87.5%
-103.6%
-22.5%
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Analyst Targets
Current price
$3.13
Low
$3.16
Analyst Mean
$3.19
High
$3.28
4 analystsHold
Full Financials
Trailing P/E-
Forward P/E12.9x
EV/EBITDA-
Price/Sales-
Dividend Yield-
Revenue Growth YoY-
Earnings Growth YoY-
Revenue Growth QoQ+92.9%
5y Revenue CAGR+74.8%
5y Earnings CAGR-
Gross Margin-
Operating Margin-
Net Margin-
ROE-
Debt / Equity-
Free Cash Flow-
Insider Ownership0.7%
Institutional Ownership63.6%
Short % of Float12.56%
Days to Cover4.9d
1 Week+63.4%
1 Month-
3 Months-
6 Months-
YTD-
1 Year-
3 Years-
5 Years-
vs 50-day SMA-
vs 200-day SMA-
vs 52w High-
vs 52w Low-
Insider Transactions
| Filer | Role | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| HALLADAY BENJAMIN | Chief Financial Officer | Sale | 6,424 | $2.70 | $0.02M | 2026-03-17 |
| KOENIG SHELDON L | Chief Executive Officer | Sale | 25,578 | $2.72 | $0.07M | 2026-03-17 |
| LOOKER BENJAMIN | Officer | Sale | 5,708 | $2.70 | $0.02M | 2026-03-17 |
| HALLADAY BENJAMIN | Chief Financial Officer | Stock | 247,430 | $0.00 | $0.00M | 2026-03-13 |
| KOENIG SHELDON L | Chief Executive Officer | Stock | 723,760 | $0.00 | $0.00M | 2026-03-13 |
Top Holders
| Holder | Type | % Held | Value | Δ Shares | As of |
|---|---|---|---|---|---|
| Blackrock Inc. | institution | 6.87% | $0.06B | +19.20% | 2025-12-31 |
| Wasatch Advisors LP | institution | 6.13% | $0.05B | +66.94% | 2026-03-31 |
| Vanguard Group Inc | institution | 5.81% | $0.05B | +23.59% | 2025-12-31 |
| Two Seas Capital Lp | institution | 4.62% | $0.04B | +22.08% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | fund | 2.82% | $0.02B | +18.34% | 2025-12-31 |
| Shaw D.E. & Co., Inc. | institution | 2.68% | $0.02B | +3208.91% | 2025-12-31 |
| Orbimed Advisors LLC. | institution | 2.32% | $0.02B | +100.00% | 2025-12-31 |
| State Street Corporation | institution | 2.30% | $0.02B | +32.41% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | fund | 2.27% | $0.02B | +2.43% | 2026-03-31 |
| Geode Capital Management, LLC | institution | 2.23% | $0.02B | +20.76% | 2025-12-31 |
| Marshall Wace LLP | institution | 2.13% | $0.02B | +117.00% | 2025-12-31 |
| Two Sigma Investments, LP | institution | 1.84% | $0.01B | +111.83% | 2025-12-31 |
| WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund | fund | 1.72% | $0.01B | -0.38% | 2025-12-31 |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | fund | 1.17% | $0.01B | -1.87% | 2026-01-31 |
| WASATCH FUNDS TRUST-Wasatch Micro Cap Fund | fund | 1.09% | $0.01B | +100.00% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | fund | 1.01% | $0.01B | +23.24% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | fund | 0.88% | $0.01B | -1.21% | 2026-01-31 |
| SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF | fund | 0.85% | $0.01B | +37.36% | 2026-03-31 |
| iShares Trust-iShares Russell 2000 Value ETF | fund | 0.53% | $0.00B | +0.46% | 2026-03-31 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | fund | 0.49% | $0.00B | -0.36% | 2026-02-28 |
| Ticker | Cap | Score | P/E | Fwd P/E | EV/EBITDA | ROE | Gross | D/E | Div |
|---|---|---|---|---|---|---|---|---|---|
| BIOA | $820M | - | - | - | - | -27.1% | 0% | 2.04 | 0.00% |
| ETON | $833M | 60 | - | 16.4 | - | - | - | - | 0.00% |
| PCRX | $937M | 58 | 193.0 | 7.0 | - | - | - | - | 0.00% |
| CRON | $990M | 5 | - | - | - | - | - | - | 0.00% |
| AMPH | $1.1B | 100 | 11.8 | 6.9 | - | - | - | - | 0.00% |
| XERS | $1.1B | 60 | 94.7 | 17.0 | - | - | - | - | 0.00% |
Peers selected by sector + industry + nearest market cap. Best in column highlighted green, worst red.
Unlock Full Financials
Growth metrics, valuation multiples, and profitability ratios on Starter+.
Recent Alerts
No alerts yet for ESPR.
Want deep analysis?
This stock isn't in the ACCE researched universe. Browse 300+ stocks with full thesis, scores, and financial models.
Browse ACCE Indices →Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.